Skip to main navigation Skip to search Skip to main content

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

  • Jose Baselga
  • , Ian Bradbury
  • , Holger Eidtmann
  • , Serena Di Cosimo
  • , Evandro de Azambuja
  • , Claudia Aura
  • , Henry Gomez
  • , Phuong Dinh
  • , Karine Kauria
  • , Veerie Van Dooren
  • , Gursel Aktan
  • , Aron Goldhirsch
  • , Tsai-Wang Chang
  • , Zsolt Horvath
  • , Maria Coccia-Portugal
  • , Julien Domont
  • , Ling-Min Tseng
  • , Georg Gunz
  • , Joo Hyuk Sohn
  • , Vladimir Semiglazov
  • Guillermo Lerzo, Marketa Palacova, Volodymur Probachai, Lajos Pusztai

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)663-640
JournalThe Lancet
Volume379
Issue number9816
DOIs
Publication statusPublished (in print/issue) - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this